| Titre | Anti-EBNA1 IgG | Anti-VCA IgG | ||
| HC (n (%)) | MS (n (%)) | HC (n (%)) | MS (n (%)) | |
| 50 | 2 (6.1) | 0 (0.0) | 1 (3.0) | 0 (0.0) |
| 100 | 1 (3.0) | 0 (0.0) | 2 (6.1) | 0 (0.0) |
| 200 | 5 (15.2) | 3 (8.8) | 1 (3.0) | 1 (2.9) |
| 400 | 6 (18.2) | 6 (17.6) | 0 (0.0) | 4 (11.8) |
| 800 | 7 (21.2) | 7 (20.6) | 5 (15.2) | 4 (11.8) |
| 1600 | 6 (18.2) | 10 (29.4) | 9 (27.3) | 15 (44.1) |
| 3200 | 2 (6.1) | 4 (11.8) | 14 (42.4) | 8 (23.5) |
| 6400 | 4 (12.1) | 4 (11.8) | 1 (3.0) | 1 (2.9) |
| 12800 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.9) |
| GMT | 720 | 1155 | 1440 | 1536 |
| n (%) titre ⩾1600 | 12 (36.4) | 18 (52.9) | 24 (72.7) | 25 (73.5) |
| p Value* | 0.17 | 0.94 | ||
*χ2 test comparing proportions of HC and MS subjects with titre ⩾1600.
EBNA1, Epstein–Barr virus nuclear antigen 1; GMT, geometric mean titre; HC, 33 healthy control subjects; MS, 34 patients with multiple sclerosis; VCA, viral capsid antigen.